Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
life sciences
national blog main
san francisco blog main
san francisco top stories
8
×
boston blog main
boston top stories
national top stories
biotech
new york blog main
new york top stories
raleigh-durham blog main
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
bristol-myers squibb
cancer
intercept pharmaceuticals
medical device
nonalcoholic steatohepatitis
startups
avexis
cancer drugs
cancer immunotherapy
celgene
colorectal cancer
What
disease
8
×
drug
known
liver
nash
roundup
approved
bio
cancer
fatty
lung
medicine
news
race
therapy
according
advanced
akcea
alnylam’s
alzheimer's
american
approval
ash
bad
bff
big
biotech
blood
brain
building
cancer’s
case
cases
centers
cigarettes
companies
conference
control
country
data
Language
unset
Current search:
photo
×
" san francisco top stories "
×
disease
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed